ABS Global & Genus v. Cytonome/ST: Federal Circuit Reverses & Remands Hydrodynamic Focusing Patent Decision
ABS Global, Inc. and Genus PLC successfully challenged a PTAB final written decision on US10583439B2, a patent covering hydrodynamic focusing apparatus and methods held by Cytonome/ST, LLC. The Federal Circuit reversed the Board's claim construction on claims 1 and 8, vacated the findings on claims 2, 6, and 9, and remanded for further proceedings — with costs awarded to the appellants after 531 days of appellate proceedings.
Federal Circuit Overturns PTAB Claim Construction in Hydrodynamic Focusing Patent Dispute
ABS Global, Inc. and Genus PLC, represented by Sidley Austin LLP, filed this appeal on 6 May 2022 at the Court of Appeals for the Federal Circuit (Case No. 22-1761), challenging a PTAB final written decision concerning US10583439B2 — a patent assigned to Cytonome/ST, LLC covering hydrodynamic focusing apparatus and methods. The underlying dispute centred on patentability, specifically an invalidity/cancellation action before the Board.
The Federal Circuit issued its decision on 19 October 2023, reversing the Board's claim construction and its final written decision on claims 1 and 8, vacating the Board's final written decision on claims 2, 6, and 9, and remanding the matter to the Board for further proceedings consistent with the Federal Circuit's opinion. Costs were awarded to the appellants. The recorded basis of termination is 'Case Remanded.'
The outcome is notable for its scope: the Federal Circuit intervened at the claim construction level, indicating a foundational disagreement with how the Board interpreted the patent's key claims. The remand leaves the ultimate patentability determination of claims 2, 6, and 9 unresolved, and the specific reasoning underpinning the claim construction reversal will govern the Board's further proceedings. The final commercial and enforcement status of US10583439B2 remains open pending those proceedings.
See Complete Case & Patent Analysis →Filing to Case Remanded in 531 days
531 days from filing to Federal Circuit decision — typical Federal Circuit appeals run 12–18 months
US10583439B2 — Hydrodynamic Focusing Apparatus and Methods
Any R&D team or product group developing hydrodynamic focusing apparatus, microfluidic cell sorting devices, or related flow cytometry instrumentation should treat US10583439B2 as an active risk until the PTAB issues its final written decision on remand. The Federal Circuit's reversal of claim construction means the operative scope of claims 1 and 8 is now defined by the appellate court's interpretation — not the Board's original analysis — and claims 2, 6, and 9 remain open. Freedom-to-operate clearance obtained prior to this decision may no longer reflect the current legal landscape.
Official order — verbatim text
The Federal Circuit's disposition — reversing the Board's claim construction and its findings on claims 1 and 8, and vacating the findings on claims 2, 6, and 9 — reflects a two-tier appellate intervention. The reversal on claim construction is the weightier holding: it signals that the Board applied a legally incorrect interpretive framework, which the Federal Circuit corrected directly. The vacatur on claims 2, 6, and 9 does not resolve patentability but nullifies the prior Board conclusions, requiring fresh analysis under the corrected standard. The award of costs to the appellants further underscores the Federal Circuit's view of the appeal's merit. The ultimate validity of the asserted claims remains open pending remand.
Federal Circuit reverses and remands: what the ruling means for both parties
Reversed in part, vacated, and remanded: what each disposition means
A Federal Circuit reversal means the appellate court found the Board committed reversible legal error — here, on claim construction for claims 1 and 8. A vacatur on claims 2, 6, and 9 nullifies those Board findings without a final merits ruling, sending them back for reconsideration under the correct legal standard. The remand requires the PTAB to conduct further proceedings consistent with the Federal Circuit's opinion.
Reversed in part + vacated + remandedABS Global and Genus PLC secure reversal on core claim construction
The appellants prevailed on the most fundamental issue: the Federal Circuit agreed that the Board's claim construction was incorrect for claims 1 and 8, and those claims were reversed outright. For claims 2, 6, and 9, the vacatur means the prior adverse findings no longer stand. Costs were also awarded to the appellants, reflecting the Federal Circuit's assessment of the appeal's merit.
Costs awarded to appellantsCytonome/ST faces renewed PTAB scrutiny under corrected claim construction
For Cytonome/ST, LLC, the decision is adverse at the appellate stage. The reversal on claims 1 and 8 means those claims were adjudged on a corrected construction, and the vacatur on claims 2, 6, and 9 reopens patentability questions before the Board. The enforceability and commercial value of US10583439B2 remain uncertain pending the outcome of the remanded proceedings.
Patentability unresolved on key claimsHydrodynamic focusing patent landscape remains unsettled post-remand
Until the PTAB issues a final written decision on remand, the validity of central claims in US10583439B2 is unresolved. Companies operating in the hydrodynamic focusing, microfluidics, and cell sorting space — including those developing flow cytometry or similar apparatus — should monitor the remand proceedings closely. Freedom-to-operate analyses referencing this patent should account for the ongoing uncertainty.
Monitor remand proceedingsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ABS Global, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Genus, PLC | Company | Search in Eureka ↗ |
| Defendant | Cytonome/ST, LLC | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Stephanie P. Koh | Attorney | Counsel for ABS Global, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Horowitz | Attorney | Counsel for ABS Global, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sidley Austin LLP | Law Firm | Representing ABS Global, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Lynn Moffett | Attorney | Counsel for Cytonome/ST, LLCSearch in Eureka ↗ |
| Defendant counsel | Pratik A. Shah | Attorney | Counsel for Cytonome/ST, LLCSearch in Eureka ↗ |
| Defendant counsel | Z.W. Julius Chen | Attorney | Counsel for Cytonome/ST, LLCSearch in Eureka ↗ |
| Defendant law firm | Akin Gump Strauss Hauer & Feld, LLP | Law Firm | Representing Cytonome/ST, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the hydrodynamic focusing and microfluidics space
Forward-looking patent and innovation intelligence derived from the ABS Global v. Cytonome/ST Federal Circuit appeal — relevant for R&D teams in microfluidics, cell sorting, and life science instrumentation.
Cytonome/ST's microfluidics patent portfolio: continuation risk
Cytonome/ST's willingness to defend US10583439B2 through Federal Circuit appeal suggests a broader portfolio strategy in hydrodynamic focusing. Companies should map Cytonome/ST's continuation and divisional filings from US14/213800 to identify claim variants that may survive or expand beyond the remanded claims.
Continuation filing watchHydrodynamic focusing patent filing trends: who is active?
Hydrodynamic focusing is a foundational microfluidics technology with growing patent activity across flow cytometry, cell sorting, and organ-on-chip applications. Tracking recent filing trends in this space can reveal which players are building offensive or defensive IP positions adjacent to the claims at issue in US10583439B2.
Filing trend analysisABS Global and Genus PLC: IP clearing strategy in reproductive biotech
ABS Global and Genus PLC operate in agricultural reproductive biotechnology — specifically sperm sorting and cell processing. Their multi-stage PTAB challenge of a hydrodynamic focusing patent signals active IP clearing in this domain. Mapping their own patent filings alongside the challenged technology can reveal where they are building freedom to operate.
Challenger portfolio mappingAdjacent claim white space: post-remand innovation opportunities
The Federal Circuit's claim construction reversal may redraw the boundaries of US10583439B2's protected scope. Design-around opportunities and adjacent innovation — particularly in nozzle geometry, sheath flow configuration, or microfluidic channel architecture — may be accessible in white space not covered by the remanded claims. An Eureka search can surface these gaps.
Design-around potentialSimilar Federal Circuit PTAB appeal cases in microfluidics and life science IP
Browse Federal Circuit appeals involving PTAB patentability decisions in microfluidics, flow cytometry, and cell sorting — the same technology domain and appellate court as Case No. 22-1761.
What this case signals for the microfluidics and cell sorting IP landscape
A Federal Circuit claim construction reversal at the PTAB level resets the validity calculus for a core hydrodynamic focusing patent — with sector-wide implications.
Claim construction errors at the PTAB remain a high-value appellate target
The Federal Circuit's willingness to reverse claim construction outright — rather than merely vacate — signals that foundational interpretive errors can unwind an entire PTAB final written decision. Challengers in IPR proceedings should invest heavily in claim construction briefing as the primary appellate lever.
US10583439B2 validity is unresolved: FTO clearance is premature
With claims 2, 6, and 9 vacated and remanded, any freedom-to-operate opinion relying on this patent being invalid is premature. R&D teams and product counsel in the hydrodynamic focusing and microfluidics space should treat this patent as potentially enforceable until PTAB issues a final decision on remand.
ABS v Cytonome/ST — key questions answered
The Federal Circuit reversed the PTAB's claim construction and its final written decision on claims 1 and 8 of US10583439B2, vacated the Board's findings on claims 2, 6, and 9, and remanded the matter for further proceedings. Costs were awarded to appellants ABS Global and Genus PLC.
US10583439B2 (application number US14/213800), held by Cytonome/ST, LLC, covers hydrodynamic focusing apparatus and methods — technology used to control fluid streams in microfluidic systems, with applications in flow cytometry, cell sorting, and related life science instrumentation.
The reversal on claims 1 and 8 means the Federal Circuit found the PTAB applied an incorrect claim construction — those claims are adjudicated under the corrected standard. The vacatur on claims 2, 6, and 9 nullifies the prior Board findings, sending them back for fresh analysis. The patent's ultimate validity on the vacated claims remains unresolved pending the PTAB remand.
The Federal Circuit's ruling does not itself invalidate the patent. Claims 2, 6, and 9 were vacated and remanded — not cancelled — meaning enforceability questions on those claims remain open. Any FTO opinion relying on this patent being invalid should be revisited in light of the remand and the corrected claim construction.
The Federal Circuit awarded costs to appellants ABS Global and Genus PLC. The specific reasoning for the cost award is not detailed in the available case record beyond the court's notation in its disposition. Cost awards at the Federal Circuit are typically associated with the prevailing party on appeal.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.